BMC Cancer (Jun 2010)

Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma

  • Moaven Omeed,
  • Hosseinnezhad Hanieh,
  • Raziee Hamid,
  • Jafarzadeh Mostafa,
  • Ghaffarzadehgan Kamran,
  • Sima Hamid,
  • Boroumand-Noughabi Samaneh,
  • Rajabi-Mashhadi Mohammad,
  • Azarian Amir,
  • Mashhadinejad Mojtaba,
  • Tavakkol-Afshari Jalil

DOI
https://doi.org/10.1186/1471-2407-10-275
Journal volume & issue
Vol. 10, no. 1
p. 275

Abstract

Read online

Abstract Background Fas (Apo-1/CD95) and its specific ligand (FasL) are key elements in apoptosis. They have been studied in different malignancies but there are few published studies about the soluble forms of these markers (i.e. sFas/sFasL) in gastric cancer. We have compared the serum levels of sFas/sFasL in gastric adenocarcinoma patients and cases with pre-neoplastic lesions as potential markers for early diagnosis, and investigated their relation with clinicopathological characteristics. Methods Fifty-nine newly-diagnosed cases of gastric adenocarcinoma who had undergone gastrectomy, along with 62 endoscopically- and histologically-confirmed non-cancer individuals were enrolled in this study. sFas/sFasL serum levels were detected by Enzyme Linked Immunosurbent Assay. Results Mean serum sFas level was significantly higher in gastric cancer patients than in control group (305.97 ± 63.71 (pg/ml) vs. 92.98 ± 4.95 (pg/ml), P N0) showed significantly higher serum levels of sFas compared to others (P = 0.044). Conclusions Production of sFas may play a critical role in the carcinogenesis of intestinal-type gastric cancer. sFas serum level may serve as a non-invasive tool for early diagnosis of gastric cancer.